Your browser doesn't support javascript.
loading
Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer.
Mohammed, Altaf; Janakiram, Naveena B; Madka, Venkateshwar; Pathuri, Gopal; Li, Qian; Ritchie, Rebekah; Biddick, Laura; Kutche, Hannah; Zhang, Yuting; Singh, Anil; Gali, Hariprasad; Lightfoot, Stan; Steele, Vernon E; Suen, Chen S; Rao, Chinthalapally V.
Afiliación
  • Mohammed A; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Janakiram NB; Current address: Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
  • Madka V; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Pathuri G; VA Medical Center, Oklahoma City, OK, USA.
  • Li Q; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Ritchie R; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Biddick L; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Kutche H; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Zhang Y; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Singh A; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Gali H; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Lightfoot S; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Steele VE; College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Suen CS; Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology-Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Rao CV; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Oncotarget ; 8(58): 97822-97834, 2017 Nov 17.
Article en En | MEDLINE | ID: mdl-29228654
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos